- Home
- LMAT vs NVCR Comparison
LMAT vs NVCR Comparison
Compare LMAT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMAT
- NVCR
- Stock Information
- Founded
- LMAT 1983
- NVCR 2000
- Country
- LMAT United States
- NVCR Switzerland
- Employees
- LMAT N/A
- NVCR N/A
- Industry
- LMAT Medical/Dental Instruments
- NVCR Medical/Dental Instruments
- Sector
- LMAT Health Care
- NVCR Health Care
- Exchange
- LMAT Nasdaq
- NVCR Nasdaq
- Market Cap
- LMAT 1.9B
- NVCR 1.9B
- IPO Year
- LMAT 2006
- NVCR 2015
- Fundamental
- Price
- LMAT $83.69
- NVCR $17.60
- Analyst Decision
- LMAT Buy
- NVCR Buy
- Analyst Count
- LMAT 6
- NVCR 7
- Target Price
- LMAT $100.80
- NVCR $32.43
- AVG Volume (30 Days)
- LMAT 152.3K
- NVCR 1.3M
- Earning Date
- LMAT 08-05-2025
- NVCR 07-24-2025
- Dividend Yield
- LMAT 0.93%
- NVCR N/A
- EPS Growth
- LMAT 30.45
- NVCR N/A
- EPS
- LMAT 1.97
- NVCR N/A
- Revenue
- LMAT $226,256,000.00
- NVCR $621,711,000.00
- Revenue This Year
- LMAT $13.88
- NVCR $5.56
- Revenue Next Year
- LMAT $8.81
- NVCR $9.19
- P/E Ratio
- LMAT $42.49
- NVCR N/A
- Revenue Growth
- LMAT 13.19
- NVCR 18.27
- 52 Week Low
- LMAT $71.42
- NVCR $14.17
- 52 Week High
- LMAT $109.58
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- LMAT 50.89
- NVCR 49.74
- Support Level
- LMAT $82.76
- NVCR $16.81
- Resistance Level
- LMAT $86.94
- NVCR $18.59
- Average True Range (ATR)
- LMAT 2.10
- NVCR 0.74
- MACD
- LMAT 0.18
- NVCR 0.08
- Stochastic Oscillator
- LMAT 47.92
- NVCR 56.18
About LMAT LeMaitre Vascular Inc.
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.